Risk Prediction for Development of Adverse Effects FOllowing Radiotherapy for Prostate Cancer

 描述（由申请人提供）：我的研究和职业重点是预测对癌症治疗的反应，特别关注对生活质量产生负面影响的不良反应。我接受过癌症生物学和遗传流行病学方面的培训，我的长期职业目标是建立一个由国家癌症研究所支持的独立研究项目，专注于预测癌症治疗结果的基因检测的开发和临床实施。我的短期研究兴趣主要集中在对放射治疗反应的遗传预测。这一研究领域，被称为“放射基因组学”，是一个令人兴奋的，相对较新的领域。这项工作的最终目标是开发一种临床上有用的基因测试 它可以根据癌症患者出现放射治疗不良反应的风险对他们进行分层。等 可以使用测试来向接受癌症诊断的个体提供信息，该信息将帮助他们与他们的医生一起沿着选择最佳的治疗过程，该过程将使不利影响最小化。这项工作有可能显著改善数百万癌症幸存者的生活质量。在K 07奖的背景下，我的近期目标是开发和测试基于遗传和非遗传风险因素的综合风险模型，用于治疗前列腺癌的放射治疗对泌尿，直肠和性的不良影响。拟议的研究旨在：1）利用大量现有的放射基因组学数据集开发风险模型，利用NCI支持的放射基因组学联盟的宝贵资源; 2）在罗切斯特大学威尔莫特癌症研究所进行的独立前瞻性研究中测试这些风险模型。拟议的研究预计将产生重要的成果，以及提供额外的经验和培训，需要我准备走上独立的职业生涯。我的研究活动将辅之以指导，教学课程和出席讲习班和国家会议。我组建了一个杰出的导师团队，由临床癌症研究、放射生物学和肿瘤学以及前列腺癌领域的领导者组成。罗切斯特医学中心和威尔莫特癌症研究所大学提供了一个出色的环境，在其中执行这一重要的工作和培训，成为临床转化癌症研究的领导者。

 DESCRIPTION (provided by applicant): My research and career focus is on predicting response to cancer treatment, with a specific concentration on adverse effects that negatively impact quality of life. I have been trained in cancer biology and genetic epidemiology, and my long-term career goal is to establish an NCI-supported independent research program focused on development and clinical implementation of genetic tests that predict for cancer treatment outcomes. My short-term research interests focus specifically on genetic predictors of response to radiation treatment. This area of research, termed 'radiogenomics', is an exciting, and relatively new field. The ultimate goal of this work is to develop a clinically useful genetic test that can stratify cancer patients as to their risk of developing adverse radiotherapy effects. Such a test could be used to provide information to individuals receiving a cancer diagnosis that will help them, along with their physician, choose the best course of treatment that will minimize adverse effects. This work has potential to significantly improve quality-of-life for millions of cancer survivors. My immediate goal within the context of this K07 award is to develop and test integrative risk models, based on genetic and non-genetic risk factors, for development of urinary, rectal and sexual adverse effects of radiotherapy used in treatment of prostate cancer. The proposed research aims to 1) develop risk models using the a large set of existing radiogenomics datasets, leveraging valuable resources of the NCI-supported Radiogenomics Consortium; and 2) test these risk models in an independent, prospective study conducted at the University of Rochester Wilmot Cancer Institute. The proposed study is expected to yield important results as well as provide additional experience and training needed to prepare me to embark on an independent career. My research activities will be complemented by mentorship, didactic coursework and attendance of workshops and national meetings. I have assembled an outstanding mentor team comprised of leaders in clinical cancer research, radiation biology and oncology, and prostate cancer. The University of Rochester Medical Center and Wilmot Cancer Institute provide an outstanding environment in which to perform this important work and train to become a leader in clinical translational cancer research.